Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Research

Doxorubicin and folic acid-loaded zinc oxide nanoparticles-based combined anti-tumor and anti-inflammatory approach for enhanced anti-cancer therapy

Authors: Soha Gomaa, Mohamed Nassef, Ghada Tabl, Somia Zaki, Asmaa Abdel-Ghany

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Zinc oxide nanoparticles (ZnONPs) have impressively shown their efficacy in targeting and therapy of cancer. The present research was designated to investigate the potential of ZnONP nanocomposites as a cancer chemotherapeutic-based drug delivery system and to assess the anti-tumor and anti-inflammatory effectiveness of ZnONP nanocomposites combination with systemic chemotherapeutic drugs doxorubicin (DOX) and folic acid (FA) in Ehrlich ascites carcinoma (EAC) tumor cell line both in vitro and in vivo.

Methods

Anti-tumor potential of ZnONP nanocomposites: ZnONPs, ZnONPs/FA, ZnONPs/DOX and ZnONPs/DOX/FA against EAC tumor cell line was evaluated in vitro by MTT assay. Anti-tumor and anti-inflammatory efficacy of ZnONP nanocomposites were analyzed in vivo by examination of the proliferation rate and apoptosis rate of EAC tumor cells by flow cytometry, splenocytes count, level of inflammatory markers interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α), as well as liver and kidney function in EAC-challenged mice.

Results

In vitro results showed that ZnONP nanocomposites showed a high anti-proliferative potency against EAC tumor cells. Furthermore, the in vivo study revealed that the treatment EAC-challenged mice with ZnONPs, ZnONPs/DOX, ZnONPs/FA and ZnONPs/DOX/FA hindered the proliferation rate of implanted EAC tumor cells through lowering their number and increasing their apoptosis rate. Moreover, the treatment of EAC-challenged mice with ZnONPs/DOX/FA markedly decreased the level of IL-6 and TNF-α and remarkably ameliorated the liver and kidney damages that were elevated by implantation of EAC tumor cells, restoring the liver and kidney functions to be close to the naïve mice control.

Conclusion

ZnONP nanocomposites may be useful as a cancer chemotherapeutic-based drug delivery system. ZnONP nanocomposites: ZnONPs/DOX, ZnONPs/FA and ZnONPs/DOX/FA regimen may have anti-inflammatory approaches and a great potential to increase anti-tumor effect of conventional chemotherapy, overcoming resistance to cancer systemic chemotherapeutics and reducing their side effects, offering a promising regimen for cancer therapy.
Literature
1.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China. CA Cancer J Clin. 2015;66(2):115–32.CrossRef
2.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
3.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics: 2021. CA Cancer J Clin. 2021;67(1):7–30.CrossRef
4.
Gomaa S, Abou-Shaefy A, Mohamed MB, Aladawy A. Combination treatment of thymoquinone-loaded gold nanoparticles and cisplatin potentiates anti-tumour activity and immunomodulatory effects in Breast cancer model. Egypt J Exp Biol (Zoo). 2018;14(1):21–1.CrossRef
5.
Argenziano M, Gigliotti CL, Clemente N, et al. Improvement in the anti-tumor efficacy of doxorubicin nanosponges in in Vitro and in mice challenged breast Tumor models. Cancers. 2020;12(1):162.PubMedCentralCrossRefPubMed
6.
Christowitz C, Davis T, Isaacs A, Van Niekerk G, Hattingh S, Engelbrecht AM. Mechanisms of doxorubicin-induced drug resistance and drug resistant Tumor growth in a murine breast tumour model. BMC Cancer. 2019;19(1):1–10.CrossRef
7.
8.
Shukla A, Hillegass JM, MacPherson MB, et al. Blocking of ERK1 and ERK2 sensitizes human Mesothelioma cells to doxorubicin. Mol Cancer. 2010;9(314):1–13.
9.
Li X, Lu Y, Liang K, Liu B, Fan Z. Differential responses to doxorubicin-induced phosphorylation and activation of akt in human Breast cancer cells. Breast Cancer Res. 2005;7(5):589–97.CrossRef
10.
Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18:409–20.CrossRefPubMed
11.
Smith L, Watson MB, O’Kane SL, Drew PJ, Lind MJ, Cawkwell L. The analysis of doxorubicin resistance in human Breast cancer cells using antibody microarrays. Mol Cancer Ther. 2006;5(8):2115–20.CrossRefPubMed
12.
13.
Dhar S, FX G, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to Prostate cancer cells by aptamer functionalized pt (IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105(45):17356–61.PubMedCentralCrossRefPubMed
14.
Kwatra D, Venugopal A, Anant S. Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer. Transl Cancer Res. 2013;2(4):330–42.
15.
Mellatyar H, Talaei S, Pilehvar-Soltanahmadi Y, Dadashpour M, Barzegar A, Akbarzadeh A, Zarghami N. 17-DMAG-loaded nanofibrous scaffold for effective growth inhibition of Lung cancer cells through targeting HSP90 gene expression. Biomed Pharmacother. 2018;105:1026–32.CrossRefPubMed
16.
Javan ES, Lotfi F, Jafari-Gharabaghlou D, Mousazadeh H, Dadashpour M, Zarghami N. Development of a magnetic nanostructure for co-delivery of metformin and silibinin on growth of Lung cancer cells: possible action through leptin gene and its receptor regulation. Asian Pac J Cancer Prev. 2022;23(2):519.CrossRef
17.
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631–51.CrossRefPubMed
18.
Dadashpour M, Firouzi-Amandi A, Pourhassan-Moghaddam M, Maleki MJ, Soozangar N, Jeddi F, Pilehvar-Soltanahmadi Y. Biomimetic synthesis of silver nanoparticles using Matricaria chamomilla extract and their potential anticancer activity against human Lung cancer cells. Mater Sci Eng C. 2018; (92): 902–12.
19.
Taccola L, Raffa V, Riggio C, et al. Zinc oxide nanoparticles as selective killers of proliferating cells. Int J Nanomed. 2011;6:1129–240.
20.
Akhtar MJ, Ahamed M, Kumar S, Khan MM, Ahmad J, Alrokayan SA. Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. Int J Nanomed. 2012;7:845–57.
21.
Thurber A, Wingett DG, Rasmussen JW, et al. Improving the selective cancer killing ability of ZnO nanoparticles using Fe doping. Nanotoxicology. 2012;6(4):440–52.CrossRefPubMed
22.
Anjum S, Hashim M, Malik SA, et al. Recent advances in Zinc Oxide nanoparticles (ZnO NPs) for Cancer diagnosis, Target Drug Delivery, and treatment. Cancers. 2021;13(18):4570.PubMedCentralCrossRefPubMed
23.
Hanley C, Layne J, Punnoose A, et al. Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles. Nanotechnology. 2008;19(29):295103.PubMedCentralCrossRefPubMed
24.
Dou Q, Fang X, Jiang S, Chee PL, Lee TC, Loh XJ. Multi-functional fluorescent carbon dots with antibacterial and gene delivery properties. RSC Adv. 2015;5(58):46817–22.CrossRef
25.
Ostrovsky S, Kazimirsky G, Gedanken A, Brodie C. Selective cytotoxic effect of ZnOnanoparticles on glioma cells. Nano Res. 2009;2(11):882–90.CrossRef
26.
27.
Bisht G, Rayamajhi S. ZnO nanoparticles: a promising anticancer agent. Nanobiomedicine. 2016;3:3–9.CrossRef
28.
Bisht G, Rayamajhi S. 2016. ZnO nanoparticles: a promising anticancer agent. Nanobiomedicine. 2016; 3: 9.
29.
Vimala K, Shanthi K, Sundarraj S, Kannan S. Synergistic effect of chemo-photothermal for Breast cancer therapy using folic acid (FA) modified zinc oxide nanosheet. J Colloid Interface Sci. 2017;488:92–108.CrossRefPubMed
30.
Ditto AJ, Shah KN, Robishaw NK, Panzner MJ, Youngs WJ, Yun YH. The interactions between L-Tyrosine based nanoparticles decorated with folic acid and Cervical Cancer cells under physiological Flow. Mol Pharm. 2012;9:3089–98.PubMedCentralCrossRefPubMed
31.
Mogheri F, Jokar E, Afshin R, Akbari AA, Dadashpour M, Firouzi-amandi A, Zarghami N. Co-delivery of metformin and silibinin in dual-drug loaded nanoparticles synergistically improves chemotherapy in human non-small cell Lung cancer A549 cells. J Drug Deliv Sci Technol. 2021; (66): 102752.
32.
Cheng W, Nie J, Xu L, Liang C, Peng Y, Liu G, Wang T, Mei L, Huang L, Zeng X. pH-Sensitive delivery vehicle based on folic acid-conjugated polydopamine-modified mesoporous silica nanoparticles for targeted Cancer Therapy. ACS Appl Mater Interfaces. 2017;9:18462–73.CrossRefPubMed
33.
Jafari-Gharabaghlou D, Dadashpour M, Khanghah OJ, Salmani-Javan E, Zarghami N. Potentiation of Folate-Functionalized PLGA-PEG nanoparticles loaded with metformin for the treatment of Breast Cancer: possible clinical application. Mol Biol Rep. 2023;50(4):3023–33.CrossRefPubMed
34.
Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004;56(8):1067–84.CrossRefPubMed
35.
Nejati K, Rastegar M, Fathi F, Dadashpour M, Arabzadeh A. Nanoparticle-based drug delivery systems to overcome gastric cancer drug resistance. J Drug Deliv Sci Technol. 2022;70:103231.CrossRef
36.
Vimala K, Sundarraj S, Paulpandi M, Vengatesan S, Kannan S. Green synthesized doxorubicin loaded zinc oxide nanoparticles regulates the Bax and Bcl-2 expression in breast and colon carcinoma. Process Biochem. 2014;49:160–72.CrossRef
37.
Guo D, Wu C, Jiang H, Li Q, Wang X, Chen B. Synergistic cytotoxic effect of different sized ZnO nanoparticles and daunorubicin against Leukemia cancer cells under UV irradiation. J Photochem Photobiol B. 2008;93(3):119–26.CrossRefPubMed
38.
Pacholski C, Kornowski A, Weller H. Self-assembly of ZnO: from nanodots to nanorods. Angew Chem Int Ed Engl. 2002;41(7):1188–91.CrossRefPubMed
39.
Beek WJ, Wienk MM, Kemerink M, Yang X, Janssen RA. Hybrid zinc oxide conjugated polymer bulk heterojunction solar cells. J Phys Chem B. 2005;109(19):9505–16.CrossRefPubMed
40.
Seow ZLS, Wong ASW, Thavasi V, Jose R, Ramakrishna S, Ho GW. Controlled synthesis and application of ZnO nanoparticles, nanorods and nanospheres in dye-sensitized solar cells. Nanotechnology. 2008;20(4):045604.CrossRefPubMed
41.
Halle W, Halder M, Worth A, Genschow E. The registry of cytotoxicity: toxicity testing in cell cultures to predict acute toxicity (LD50) and to reduce testing in animals. Altern Lab Anim. 2003;31(2):89–9.CrossRefPubMed
42.
Gothoskar SV, Ranadive KJ. Anticancer screening of SAN-AB; an extract of marking nut, Semicarpus anacardium. Indian J Exp Biol. 1971;9:372–5.PubMed
43.
Abdel Salam SA, Salem M, Nassef M, Abdu S, El-Adl R. Efficacy of combined administration of chemoimmunotherapy with bone marrow cells or granulocyte-colony stimulating factor-mobilized stem cells on expansion of myeloid and stem cells. Clin Cancer Investig J. 2017;6(1):73–3.CrossRef
44.
Nassef M. Immunohematological impacts induced by clomazone in Swiss albino mice: ameliorative role of vitamin C. Egypt J Exp Biol (Zoo). 2017;13(1):91–101.
45.
Gomaa S. Adverse effects induced by diclofenac, ibuprofen, and Paracetamol toxicity on immunological and biochemical parameters in Swiss albino mice. J Basic Appl Zool. 2018;79(1):1–9.CrossRef
46.
Brabec V, Kasparkova J. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor Drugs. Drug Resist Updat. 2005;8:131–46.CrossRefPubMed
47.
Torigoe T, Izumi H, Ishiguchi H, et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents. 2005;5(1):15–27.CrossRefPubMed
48.
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141–60.PubMedCentralPubMed
49.
Jiang H, Cui J, Chu H, et al. Targeting IL8 as a sequential therapy strategy to overcome chemotherapy resistance in advanced gastric cancer. Cell Death Discov. 2022;8(1):1–13.CrossRef
50.
51.
Sundraraman G, Jayakumari LS. Meticulous taxifolin releasing performance by the zinc oxide nanoparticles: as a short road to drug delivery system for cancer therapeutics. J Clust Sci. 2020;31(1):241–55.CrossRef
52.
Mona MA, Mottaleb A. Biodegradable thymoquinone nanoparticles for higher therapeutic efficiency in murine Colorectal cancer. Int J Pharm Sci Res. 2016;7:436–50.
53.
Kocbek P, Teskač K, Kreft ME, Kristl J. Toxicological aspects of long-term treatment of keratinocytes with ZnO and TiO2 nanoparticles. Small. 2010;6(17):1908–17.CrossRefPubMed
54.
Ismail AF, Ali MM, Ismail LF. Photodynamic therapy mediated antiproliferative activity of some metal-doped ZnO nanoparticles in human liver adenocarcinoma HepG2 cells under UV irradiation. J Photochem Photobiol B: Biol. 2014;138:99–108.CrossRef
55.
56.
Wang J, Gao S, Wang S, Xu Z, Wei L. Zinc oxide nanoparticles induce toxicity in CAL 27 Oral cancer cell lines by activating PINK1/Parkin-mediated mitophagy. Int J Nanomed. 2018;13:3441.CrossRef
57.
Arakelova ER, Grigoryan SG, Arsenyan FG, Babayan NS, Grigoryan RM, Sarkisyan NK. In vitro and in vivo anticancer activity of nanosize zinc oxide composites of doxorubicin. Int J Chem Eng 2014; 8(1):33–38.
58.
Berardis B, Civitelli G, Condello M, et al. Exposure to ZnO nanoparticles induces oxidative stress and cytotoxicity in human colon carcinoma cells. Toxicol Appl Pharmacol. 2010;246(3):116–27.CrossRefPubMed
59.
Berthiaume JM, Wallace KB. Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment. Cardiovasc Toxicol. 2007;7(3):178–91.CrossRefPubMed
60.
Kumar A, White J, Christie RJ, Dimasi N, Gao C. Antibody-drug nanocomposites. Annu Rep Med Chem. 2017;50:441–80.
61.
Lakshminarayanan R, Chi-Jin EO, Loh XJ, Kini RM, Valiyaveettil S. Purification and characterization of a vaterite-inducing peptide, pelovaterin, from the eggshells of Pelodiscus Inensis (Chinese Soft-shelled Turtle). Biomacromolecules. 2005;6(3):1429–37.CrossRefPubMed
62.
Mohanty S, Saha S, Hossain MS, et al. ROS-PIASγ cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors. Cell Death Dis. 2014;5(1):e1021–1.PubMedCentralCrossRefPubMed
63.
Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging. 2016;8(4):603–19.PubMedCentralCrossRefPubMed
64.
Chakraborty S, Mazumdar M, Mukherjee S, et al. Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures bax-dependent apoptosis of non-small cell lung carcinoma cells. FEBS Lett. 2014;588(4):549–59.CrossRefPubMed
65.
Lin W, Xu Y, Huang CC, et al. Toxicity of nano-and micro-sized ZnO particles in human lung epithelial cells. J Nanoparticle Res. 2009;11(1):25–39.CrossRef
66.
Sharma V, Anderson D, Dhawan A. Zinc oxide nanoparticles induce oxidative stress and genotoxicity in human liver cells (HepG2). J Biomed Nanotechnol. 2011;7(1):98–9.CrossRefPubMed
67.
Bai DP, Zhang XF, Zhang GL, Huang YF, Gurunathan S. Zinc oxide nanoparticles induce apoptosis and autophagy in human Ovarian cancer cells. Int J Nanomedicine. 2017;12:6521–35.PubMedCentralCrossRefPubMed
68.
Wang SW, Lee CH, Lin MS, et al. ZnO nanoparticles induced caspase-dependent apoptosis in gingival squamous cell carcinoma through mitochondrial dysfunction and p70S6K signaling pathway. Int J Mol Sci. 2020;21(5):1612.PubMedCentralCrossRefPubMed
69.
Rajapriya M, Sharmili SA, Baskar R, et al. Synthesis and characterization of zinc oxide nanoparticles using Cynara scolymus leaves: enhanced hemolytic, antimicrobial, antiproliferative, and photocatalytic activity. J Clust Sci. 2020;31(4):791–801.CrossRef
70.
Vimala K, Sundarraj S, Paulpandi M, Vengatesan S, Kannan S. Green synthesized doxorubicin loaded zinc oxide nanoparticles regulates the Bax and Bcl-2 expression in breast and colon carcinoma. Process Biochem. 2014;49(1):160–72.CrossRef
71.
Nagajyothi PC, Cha SJ, Yang IJ, Sreekanth TVM, Kim KJ, Shin HM. Antioxidant and anti-inflammatory activities of zinc oxide nanoparticles synthesized using Polygala tenuifolia root extract. J Photochem Photobiol B: Biol. 2015;146:10–7.CrossRef
72.
Thatoi P, Kerry RG, Gouda S, et al. Photo-mediated green synthesis of silver and zinc oxide nanoparticles using aqueous extracts of two mangrove plant species, Heritiera fomes and Sonneratia apetala and investigation of their biomedical applications. J Photochem Photobiol B: Biol. 2016;163:311–8.CrossRef
73.
Özcan A, Sahin D, Impellizzieri D, et al. Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue remodeling in psoriasis. J Invest Dermatol. 2020;140(5):1003–14.CrossRefPubMed
74.
Jiang J, Pi J, Cai J. The advancing of zinc oxide nanoparticles for biomedical applications. Bioinorg Chem Appl. 2018;3:1–18.CrossRef
75.
Wu Y, Shi W, Wang H, et al. Anti-ST2 nanoparticle alleviates lung inflammation by targeting ILC2s-CD4 + T response. Int J Nanomedicine. 2020;15:9745.PubMedCentralCrossRefPubMed
76.
Liu J, Liu Z, Pang Y, Zhou H. The interaction between nanoparticles and immune system: application in the treatment of inflammatory Diseases. J Nanobiotechnol. 2022;20(1):1–25.
77.
Zeng Y, Xiang Y, Sheng R, et al. Polysaccharide-based nanomedicines for cancer immunotherapy: a review. Bioactive Mater. 2021;6(10):3358–82.CrossRef
78.
Hira I, Kumar A, Kumari R, Saini AK, Saini RV. Pectin-guar gum-zinc oxide nanocomposite enhances human lymphocytes cytotoxicity towards lung and breast carcinomas. Mater Sci Eng C. 2018;90:494–503.CrossRef
79.
Agarwal H, Shanmugam V. A review on anti-inflammatory activity of green synthesized zinc oxide nanoparticle: mechanism-based approach. Bioorg Chem. 2020;94:103423.CrossRefPubMed
80.
Mousavi SM, Behbudi G, Gholami A, et al. Shape-controlled synthesis of zinc nanostructures mediating macromolecules for biomedical applications. Biomater Res. 2022;26(1):1–20.CrossRef
81.
Roy R, Singh SK, Das M, Tripathi A, Dwivedi PD. Toll-like receptor 6 mediated inflammatory and functional responses of zinc oxide nanoparticles primed macrophages. Immunology. 2014;142(3):453–64.PubMedCentralCrossRefPubMed
82.
Bashandy SA, Alaamer A, Moussa SAA, Omara EA. Role of zinc oxide nanoparticles in alleviating hepatic fibrosis and nephrotoxicity induced by thioacetamide in rats. Can J Physiol Pharmacol. 2018;96(4):337–44.CrossRefPubMed
83.
Murta BMT, Machado JS, Zaparoli M, Lara VC, Murta EFC. The relationship of host immune cells, cytokine and nitric oxide production to Tumor cells in ovarian carcinoma. Sao Paulo Med J. 1999;117:87–92.CrossRefPubMed
84.
Kim CS, Nguyen HD, Ignacio RM, et al. Immunotoxicity of zinc oxide nanoparticles with different size and electrostatic charge. Int J Nanomedicine. 2014;9(2):195–205.PubMedCentralPubMed
85.
Radwan AM, Aboelfetoh EF, Kimura T, Mohamed TM, El-Keiy MM. Fenugreek-mediated synthesis of zinc oxide nanoparticles and evaluation of its in vitro and in vivo antitumor potency. Biomed Res Ther. 2021;8(8):4483–96.CrossRef
86.
Nabeel AI. Samarium enriches antitumor activity of ZnO nanoparticles via downregulation of CXCR4 receptor and cytochrome P450. Tumour Biol. 2020;42(3):1010428320909999.CrossRefPubMed
87.
Awadalla A, Hussein AM, Ali M, et al. Possible mechanisms for the renoprotective action of adipose-derived mesenchymal stem cells with CD44-targeted hyaluronic acid against renal ischemia. Life Sci. 2021;272(1):119221.CrossRefPubMed
Metadata
Title
Doxorubicin and folic acid-loaded zinc oxide nanoparticles-based combined anti-tumor and anti-inflammatory approach for enhanced anti-cancer therapy
Authors
Soha Gomaa
Mohamed Nassef
Ghada Tabl
Somia Zaki
Asmaa Abdel-Ghany
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11714-4

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Correspondence

Using administrative registries as a source for population-based cancer incidence and mortality

Research

Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study

Research

The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells

Research

Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study

Research

Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest

Research

Effectiveness of CT radiomic features combined with clinical factors in predicting prognosis in patients with limited-stage small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits